矩阵金属蛋白酶抑制对由于体积过载导致的心室重塑的影响
Amanda L Chancey1, Gregory L Brower, J Thomas Peterson
1Department of Anatomy, Physiology, and Pharmacology, Auburn University, Auburn, Ala 36849, USA.
Circulation
|May 9, 2002
概括
在心力衰竭的老鼠模型中,矩阵金属蛋白酶 (MMP) 抑制疗法显著降低了左心室 (LV) 重塑和高. 这种治疗减弱了心室扩张,并在慢性体积过载期间保持了心脏功能.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学 是一个学科.
- 生物医学工程 生物医学工程
背景情况:
- 左心室 (LV) 缩和扩张是对慢性体积过载的补偿反应.
- 心肌重塑可能会变得不适应,导致心力衰竭.
- 增加的矩阵金属蛋白酶 (MMP) 活性与体积过载模型中的LV扩张有关.
研究的目的:
- 调查MMP抑制治疗对LV大小和功能的影响.
- 评估PD 166793 (1毫克x公斤(-1) xd(-1)) 在大小过载引起心力衰竭的小鼠模型中.
主要方法:
- 鼠经历了下腹腹腔大气管 (体积过载) 或假手术.
- 组包括治疗和未治疗的,以及治疗和未治疗的假对照.
- PD 166793用于评估MMP抑制疗法.
主要成果:
- 与对照组相比,两组管组的LV重量都增加了.
- 与未经治疗的鱼组相比,经过治疗的鱼组在8周内显示出较低的LV重量 (P<0.012).
- 在接受治疗的囊组中,心室扩张显著减少.
结论:
- 在慢性体积过载中,MMP抑制疗法显著减弱心肌重塑.
- 该疗法防止了 LV 扩张,并显著减少了 LV 缩.
- 在接受MMP抑制治疗的老鼠中,心室功能被保留了.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


